Moxifloxacin (CAS 186286-86-8) is a recent fluoroquinolone addressed to the treatment of respiratory infections, although clinical efficacy has been shown also in the therapy of urinary tract diseases.The in vitro activity of moxifloxacin against one encapsulated strain of Klebsiella pneumoniae was determined by means of time-kill curves and by evaluation of effects of subinhibitory concentrations on bacterial morphology by means of scanning electron microscopy. Moreover, the efficacy and time requested to eradicate the same strain from lungs was determined after intratracheal infection of guinea pigs.K. pneumoniae was rapidly killed by moxifloxacin at concentrations greater than the minimum inhibitory concentration (MIC). Subinhibitory concentrations (1/4 and 1/8 of the MIC ) induced filamentation in a remarkable portion of Zusammenfassung Antibakterielle Wirkung in vitro von Moxifloxacin und sein Einfluβ auf die Elimination von Klebsiella pneumoniae in den Lungen eines Versuchstiermodells Moxifloxacin (CAS 186286-86-8) ist ein neuartiges Fluorchinolon zur Behandbacteria. A progressive decrease in the bacterial content of lungs was observed during the 48-h period, with statistically significant differences compared with the control animals. In conclusion, this study provides in vivo evidence of the antimicrobial properties of moxifloxacin against K. pneumoniae. lung von Atemwegsinfektionen, das auch in der Behandlung von Krankheiten der Harnwege gute klinische Wirkungen gezeigt hat. Die In-vitro-Aktivität von Moxifloxacin gegen einen verkapselten Stamm von Klebsiella pneumoniae wurde mit Hilfe Key words Antibacterial drug CAS 186286-86-8 Klebsiella pneumoniae Moxifloxacin, bactericidal activity, guinea pig Arzneim.-Forsch./Drug Res. 55, No. 8, 473−477 (2005) Arzneim.-Forsch./Drug Res. 55, No. 8, 473−477 (2005) Drago et al. − Moxifloxacin 473